CCR2 and neoplasm: Though we had identified that the primary effector cell responsible for the anti-tumor effects of WGP are CCR2+ infiltrating monocytes/macrophages, we reasoned that these immune changes may also impact the overall TME in a way that could make adaptive immune cells more responsive to checkpoint blockade therapy.